0.02Open0.02Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover110.31%IV39.07%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier27DDays to Expiry0.02Extrinsic Value100Contract SizeAmericanOptions Type-0.0368Delta0.0661Gamma203.50Leverage Ratio-0.0018Theta-0.0001Rho-7.49Eff Leverage0.0009Vega
Geron Stock Discussion
Almost low enough
Geron Corp - Receives $250 Million at Closing, $125 Million in Debt Available
Royalty Pharma to Acquire Royalty Interest in Geron’s Rytelo for $125 Million
Achieved $28.2 million in RYTELO(TM) (imetelstat) net product revenue in first full quarter of sales
Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt
No comment yet